AngioDynamics, Inc. (ANGO) vs Climb Bio, Inc. (CLYM)

A side-by-side comparison of AngioDynamics, Inc. and Climb Bio, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ANGO

AngioDynamics, Inc.

$645M

$15.61HealthcareDelayed quote: Oct 6, 2026, 9:30 AM EDT

CLYM

Climb Bio, Inc.

$637M

$11.12HealthcareDelayed quote: Oct 6, 2026, 9:30 AM EDT

Total return — ANGO vs CLYM

growth of $100 · dividends reinvested · last 2y

ANGO +112.3% (+45.7%/yr)CLYM +41.1% (+18.8%/yr)ANGO compounded faster over this window

ANGO CLYM

ANGO vs CLYM: by the numbers

•ANGO is the larger company ($645M vs $637M market cap).
•Both run net losses; CLYM's is the smaller (0.00% vs -11.48% net margin).

Metrics side by side

Valuation

Metric	ANGO	CLYM
P/S ratio	2.02	N/A
P/B ratio	3.78	2.66
FCF yield	0.08%	N/A

Profitability

Metric	ANGO	CLYM
Gross margin	54.62%	0.00%
Operating margin	-12.47%	0.00%
Net margin	-11.48%	0.00%
ROE	-21.51%	-24.06%
ROIC	-20.75%	-26.94%

Growth (annualized)

Metric	ANGO	CLYM
Revenue CAGR (5Y)	1.93%	N/A
FCF CAGR (5Y)	-51.49%	N/A
Total return CAGR (5Y)	-10.80%	N/A

Go deeper

Full ANGO analysis Full CLYM analysis Interactive comparison tool

Dig into the metrics

AngioDynamics ROE Climb Bio ROE AngioDynamics operating margin Climb Bio operating margin AngioDynamics revenue growth Climb Bio revenue growth AngioDynamics free cash flow Climb Bio free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.